Targeted Liquid Biopsy OncoKit

Protocol automated using Magnis NGS Prep System

Analysis software to screen for the study of the main biomarkers of clinical interest in non-small cell lung cancer and other solid tumors

24 rxn

NGS sequencing

IMG-415

Compatible sequencers: Illumina NextSeq500/550 and NextSeq550Dx System. Panel fully automated on Magnis NGS Prep System Dx

Protocol automated using Magnis NGS Prep System
  • Characterization of ctDNA obtained from a liquid biopsy sample.
  • SNV, indel, genetic fusion, and CNV detection in a single DNA sample.
  • Bioinformatic analysis with the Data Genomics software and semi-automated generation of reports, which include both functional and clinical classification of the variants.
  • Based on high sensitivity RNA-probe technology with UMI barcoding (unique molecular identifiers).
  • Mean coverage: 7300X, with mean coverage after UMI analysis: 2500X.
  • The specificity, sensitivity, and repeatability of this kit are >99% and reproducibility is >97%. Coverage (at a read depth >100X) and uniformity of bases covered at >20X is >96%.
  • Limit of detection: SNVs, indels and structural variants: 1%; CNVs: gains of 2.9 copies.
  • Compliant with ISO 9001 and ISO 14001 quality specifications regarding manufacturing materials.
  • CE-IVD-marked analysis software.
  • Compatible sequencers: Illumina NextSeq500/550 and NextSeq550Dx System
  • Number of reactions: 24
  • Number of samples per run: 8 samples in a NextSeq HIGH output cartridge (150 cycles)
  • Sequencing: Paired-end (2 x 75 cycles)
  • Sample type: Circulating cell-free DNA from a liquid biopsy sample
  • Amoung of input DNA: 10-50 ng
  • Limit of detection: SNVs, indels and structural variants: 1%; CNVs: gains of 2.9 copies
  • Panel fully automated on Magnis NGS Prep System Dx

Targeted Liquid Biopsy OncoKit

Fill in the form to request this kit.

Call us at +34 963 212 340

Or write to us at info@healthincode.com